Hydantoin derivatives useful as metalloproteinase inhibitors

Details for Australian Patent Application No. 2005315459 (hide)

Owner AstraZeneca AB

Inventors Persson, David Jonas; Waterson, David

Agent Freehills

Pub. Number AU-B-2005315459

PCT Pub. Number WO2006/064218

Priority 0427403.1 15.12.04 GB

Filing date 14 December 2005

Wipo publication date 22 June 2006

Acceptance publication date 8 January 2009

International Classifications

C07D 401/12 (2006.01) Heterocyclic compounds containing two or more hetero rings

A61K 31/4166 (2006.01)

A61K 31/445 (2006.01) - Non-condensed piperidines, e.g. piperocaine

A61P 19/02 (2006.01) Drugs for skeletal disorders

Event Publications

14 June 2007 PCT application entered the National Phase

  PCT publication WO2006/064218 Priority application(s): WO2006/064218

8 January 2009 Application Accepted

  Published as AU-B-2005315459

7 May 2009 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005315460-Portable faeces container

2005315458-Process for the preparation of 4-(6-chloro-2, 3-methylenedioxyanilino)-7-(2-(4-methyl piperazin-1-yl) ethoxy)-5-tetrahydropyran-4-yloxyquinazoli ne, their intermediates and crystalline salts thereof